ARV-110 in Combination with Abiraterone
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer Metastatic
Conditions
Prostate Cancer Metastatic
Trial Timeline
Feb 1, 2022 → Apr 10, 2025
NCT ID
NCT05177042About ARV-110 in Combination with Abiraterone
ARV-110 in Combination with Abiraterone is a phase 1 stage product being developed by Arvinas for Prostate Cancer Metastatic. The current trial status is completed. This product is registered under clinical trial identifier NCT05177042. Target conditions include Prostate Cancer Metastatic.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05177042 | Phase 1 | Completed |
Competing Products
20 competing products in Prostate Cancer Metastatic